The Staying Power of Small Molecules
October 8, 2026
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
4 min read
False
Advertisement
Top Stories
Browse By Topic
Newsletters
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.
Voices in the Community
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine
View ProfileMusings from The Power List: Claudia Zylberberg
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
Latest News
All the latest Medicine Maker articles.
Building a CAR-T CMC Strategy on a Limited Budget
October 6, 2026
Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes
7 min read
Musings from The Power List: Andres Sirulnik
October 5, 2026
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
4 min read
The Resilience Prescription
October 2, 2026
We asked the 2026 Power List how the pharmaceutical industry can prepare for geopolitical, economic, regulatory, and scientific uncertainty
5 min read
Video: From Accounting to Action on Pharma Sustainability
October 2, 2026
Ahead of CPHI Milan’s Sustainability Summit, Silvia Forroova and Rob Williams discuss how shared standards and supplier partnerships can turn commitments into measurable progress.
1 min read
Development & Clinical
Cell & Gene
Interviews
Business & Trends
Technology & Manufacturing
Power List
Musings from The Power List: Fabian Gerlinghaus
October 1, 2026
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
3 min read
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
September 30, 2026
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications
10 min read
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
September 30, 2026
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
2 min read
How Companion Diagnostics Can Support Targeted Drug Launches
September 29, 2026
Coordinated development and practical testing pathways can help ensure eligible patients are identified from the point of approval
5 min read
Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read
Musings from The Power List: Renee Aguiar-Lucander
September 28, 2026
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
2 min read
Newsletters
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.